Erratum: Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors

The expression of retinoid acid receptors α (RARα) and β (RARβ) and estrogen receptor α (ERα) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARα was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARα expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARβ and ERα expression did not correlate with RARα tumor characteristics or PFS and survival.

本研究采用免疫组织化学染色法（immunohistochemistry）与蛋白质印迹法（Western blotting），对正常卵巢、浆液性囊腺瘤（n=20）、交界性浆液性肿瘤（n=14）及浆液性卵巢癌（n=47）组织中视黄酸受体α（retinoid acid receptors α, RARα）、视黄酸受体β（retinoid acid receptors β, RARβ）与雌激素受体α（estrogen receptor α, ERα）的表达水平进行了检测，并分析了癌组织中上述受体的表达与临床分期、病理分级、无进展生存期（progress-free survival, PFS）及生存期的相关性。在良性囊腺瘤、交界性肿瘤、低分期与高分期肿瘤组织中，RARα的表达水平呈逐渐升高趋势（p < 0.001）。在Ⅲ期G3级浆液性癌组织中，RARα高表达为独立预后因素，与一线化疗（紫杉醇（taxol）与卡铂（carboplatin））的较低化疗响应率及更短的无进展生存期显著相关（p < 0.002）。RARβ与ERα的表达水平与RARα相关肿瘤特征、无进展生存期及生存期均无相关性。